When CDMO Lonza shelled out $5.5 billion for capsule maker Capsugel in 2017, it made a big bet the booming capsule market would drive revenue. Now, with demand continuing to grow, Lonza is putting another down payment on capsules to keep up.
Lonza will spend $93 million to expand its capsule manufacturing by 15% across eight sites globally in a move to add more than 30 billion doses per year to its capacity, the Swiss manufacturer said Thursday.
The company’s expansion of its Capsugel technology manufacturing comes amid booming demand for capsules in the pharmaceutical and nutritional health fields, Lonza said. Back in 2019, Lonza bumped up capacity in its Capsules and Health Ingredients (CHI) unit, which includes the Capsugel portfolio, by 10% to keep up with demand.
Lonza’s newest investment will be doled out to eight sites including: Bornem, Belgium; Colmar, France; Greenwood, Indiana; Haryana, India; Jakarta, Indonesia; Puebla, Mexico; Sagamihara, Japan; and Suzhou, China.
The company’s capsule growth will allow Lonza to focus on next-gen dosage forms in its CHI unit, which includes lipid multiparticulates and several time-release dosages currently in the research phase, Lonza said.
When it acquired Capsugel, then a U.S.-based contract capsule and drug producer, for a cool $5.5 billion in 2017, Lonza envisioned major growth ahead as the leading manufacturer of pharmaceutical capsules.
Soon after the buyout, Lonza predicted would hit $7.9 billion in annual revenue by 2022—a number that could still be attainable. In the first half of 2020, Lonza hit $3.07 billion in revenue at about 3.3% growth.
At the time of the purchase, Capsugel touted 3,600 employees and 13 facilities on three continents.
Lonza is in a period of change after appointing a new CEO, Roche veteran Pierre-Alain Ruffieux, in June after Marc Funk ended his nine-month tenure in the top spot in November.
The company is working with Maryland biotech Moderna to produce an mRNA-based COVID-19 shot, with the partnership aiming for 1 billion doses per year if the shot secures regulatory approval.
By Kyle Blankenship
Source: fiercepharma.com
Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.
Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.
The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world.
